Two-thirds back: the extension nobody expected to be the headline
A withdrawal trial answers a narrower question than it appears to. This piece states which question.
The Ledger — 2024
Prices, margins, coverage and the cost stack.
Mexico caps semaglutide prescribing to 21 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Germany declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Australia caps liraglutide prescribing to 10 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The badge economy, and what it is actually certifying
What a verification mark would have to carry to be checkable: a date, a lot, a method, a submitter and a link to the report.
Norway caps liraglutide prescribing to 9 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Argentina declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Australia caps tirzepatide prescribing to 17 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Maintenance dosing: what is licensed, what is practised, and what is evidenced
Dose reduction is not withdrawal, and the trials that tested withdrawal cannot be read as testing it.
The lead-in, the randomisation, and the year that followed
A withdrawal trial answers a narrower question than it appears to. This piece states which question.
South Africa caps tirzepatide prescribing to 17 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
We split six vials four ways and posted them
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
South Korea caps semaglutide prescribing to 18 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Singapore declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
A tested vial is evidence about a vial
A result on one vial generalises to a batch only if the vial was drawn in a way that makes it representative — and nobody records how it was drawn.
Ireland caps exenatide prescribing to 19 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The lowest effective dose is a real concept with almost no data behind it
A survey of the maintenance evidence, which is shorter than the survey of the withdrawal evidence.
Ireland caps tirzepatide prescribing to 17 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The lead-in, the randomisation, and the year that followed
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
The United Arab Emirates caps exenatide prescribing to 19 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.